Doug Krafte is Senior Vice President of Ion Channels/Transporters at OmniAb and serves as the Icagen Ion Channel Technology Site Head. Dr. Krafte has over 30 years of experience in the pharmaceutical and biotech industry managing research sites and R&D programs. Previously, he was Chief Scientific Officer at Icagen, Inc. and an executive officer there where he helped establish collaborative programs with Roche and the Cystic Fibrosis Foundation. Dr. Krafte previously was Executive Director & Site Head for the U.S. arm of Pfizer’s Pain & Sensory Disorders Research Unit, where on the Emerging Science Fund he evaluated a wide range of asset and technology opportunities across all therapeutic and platform areas. He has also held positions at Boehringer Ingelheim and Aurora Biosciences focused on drug discovery projects and technology development. Dr. Krafte is the author of multiple peer-reviewed scientific papers and several patents and has advised entrepreneurial groups for North Carolina universities. Dr. Krafte completed his post-doctoral training at the California Institute of Technology in Molecular Neurobiology, received an MS/PhD in Physiology from the University of Rochester and a BS in molecular biology from Vanderbilt University.